Equities

Genor Biopharma Holdings Ltd

Genor Biopharma Holdings Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.65
  • Today's Change0.000 / 0.00%
  • Shares traded2.19m
  • 1 Year change+41.03%
  • Beta1.2374
Data delayed at least 15 minutes, as of Sep 12 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,1651,5892,201
Total Receivables, Net6983133
Total Inventory5.674750
Prepaid expenses------
Other current assets, total1.341.343.76
Total current assets1,2411,7202,387
Property, plant & equipment, net60205223
Goodwill, net182222
Intangibles, net92141149
Long term investments------
Note receivable - long term272076
Other long term assets------
Total assets1,4472,1152,863
LIABILITIES
Accounts payable142132130
Accrued expenses224159
Notes payable/short-term debt0030
Current portion long-term debt/capital leases3.236.767.60
Other current liabilities, total638188
Total current liabilities230260313
Total long term debt3.922220
Total debt7.162957
Deferred income tax121213
Minority interest1.892.742.92
Other liabilities, total111523
Total liabilities258313373
SHAREHOLDERS EQUITY
Common stock0.070.070.07
Additional paid-in capital9,3989,3769,291
Retained earnings (accumulated deficit)(8199)(7564)(6793)
Treasury stock - common(5.2)(5.2)(5.2)
Unrealized gain (loss)------
Other equity, total(5.09)(4.34)(2.95)
Total equity1,1891,8022,490
Total liabilities & shareholders' equity1,4472,1152,863
Total common shares outstanding504501496
Treasury shares - common primary issue3.793.796.63
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.